BDSI announces public offering after paying $30M for drug rights
April 11, 2019 at 07:25 AM EDT
In a pair of announcements, Raleigh's BioDelivery Sciences International, announced the $30 million acquisition of exclusive U.S. commercialization rights to a Japanese drug. In the hours following that deal, BDSI also announced a public offering of its common stock.
